Furthermore, we identified USP8 is a novel DUB of GPR34, which could rescue the effects caused by GPR34 deletion, and targeting USP8 with DUB-IN-3 could restrain tumor growth in ATC (Figure 6I), offering a new potential strategy for this treatment-resistant cancer. Here, USP8 is linked to neoplasm.